Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737405 | 0.89 | PRKAA2 (0.42) | LMNAKDM4EMEN1ALDH1A1BRCA1 | |
| SCHEMBL24214203 | 0.83 | MAPK1 (0.50) | LMNAKDM4EKMT2AL3MBTL1HRH3 | |
| SCHEMBL30737412 | 0.79 | SORT1 (0.61) | HRH3PRKAA2 | |
| SCHEMBL30737193 | 0.78 | LMNA (0.51) | LMNAKDM4EMEN1ALDH1A1BRCA1 | |
| SCHEMBL30737189 | 0.78 | GPR119 (0.49) | PRKAA2 | |
| SCHEMBL31646829 | 0.77 | L3MBTL1 (0.54) | LMNAKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL693093 | 0.77 | HRH3 (0.59) | LMNAKDM4EMEN1ALDH1A1BRCA1 | |
| SCHEMBL31646216 | 0.77 | MAPT (0.50) | LMNAKDM4EMEN1ALDH1A1BRCA1 | |
| SCHEMBL3586183 | 0.76 | LMNA (0.60) | LMNAKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL30737060 | 0.75 | L3MBTL1 (0.52) | LMNAMEN1ALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | LMNA 2590/4885KDM4E 4709/4885MEN1 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.